To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease

Trial Profile

To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Aclidinium bromide/formoterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms ASTUTE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 30 Jun 2017 Planned End Date changed from 24 Aug 2018 to 3 Dec 2018.
    • 30 Jun 2017 Planned primary completion date changed from 24 Aug 2018 to 3 Dec 2018.
    • 30 Jun 2017 Planned initiation date changed from 25 Aug 2017 to 4 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top